75 related articles for article (PubMed ID: 24926991)
1. Targeting the NF-E2-related factor 2 pathway: a novel strategy for glioblastoma (review).
Zhu J; Wang H; Fan Y; Lin Y; Zhang L; Ji X; Zhou M
Oncol Rep; 2014 Aug; 32(2):443-50. PubMed ID: 24926991
[TBL] [Abstract][Full Text] [Related]
2. Targeting the NF-E2-related factor 2 pathway for overcoming leukemia.
Harifi-Mood MS; Daroudi M; Darroudi M; Naseri K; Samarghandian S; Farkhondeh T
Int J Biol Macromol; 2023 Dec; 253(Pt 8):127594. PubMed ID: 37890739
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological targeting of one‑carbon metabolism as a novel therapeutic strategy for glioblastoma.
Sun Y; Mu G; Xue Z; Li X; Lin X; Han M
J Transl Med; 2023 Jun; 21(1):424. PubMed ID: 37386497
[No Abstract] [Full Text] [Related]
4. Role of the Keap1-Nrf2 pathway in cancer.
Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
Adv Cancer Res; 2014; 122():281-320. PubMed ID: 24974185
[TBL] [Abstract][Full Text] [Related]
5. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.
Wu SH; Bi JF; Cloughesy T; Cavenee WK; Mischel PS
Cancer Biol Med; 2014 Dec; 11(4):255-63. PubMed ID: 25610711
[TBL] [Abstract][Full Text] [Related]
6. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.
Huang RY; Neagu MR; Reardon DA; Wen PY
Front Neurol; 2015; 6():33. PubMed ID: 25755649
[TBL] [Abstract][Full Text] [Related]
7. Tumour suppressor TRIM33 targets nuclear β-catenin degradation.
Xue J; Chen Y; Wu Y; Wang Z; Zhou A; Zhang S; Lin K; Aldape K; Majumder S; Lu Z; Huang S
Nat Commun; 2015 Feb; 6():6156. PubMed ID: 25639486
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target.
Jackson M; Hassiotou F; Nowak A
Carcinogenesis; 2015 Feb; 36(2):177-85. PubMed ID: 25504149
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma heterogeneity and cancer cell plasticity.
Friedmann-Morvinski D
Crit Rev Oncog; 2014; 19(5):327-36. PubMed ID: 25404148
[TBL] [Abstract][Full Text] [Related]
10. Severe hypouricemia: biochemical expression of asymptomatic xanthinuria.
Ducorps M; Hélie C; Mayaudon H; Bauduceau B
Clin Chem; 1995 Dec; 41(12 Pt 1):1789-90. PubMed ID: 7497632
[No Abstract] [Full Text] [Related]
11. Crosstalk between Nrf2 and Notch signaling.
Wakabayashi N; Chartoumpekis DV; Kensler TW
Free Radic Biol Med; 2015 Nov; 88(Pt B):158-167. PubMed ID: 26003520
[TBL] [Abstract][Full Text] [Related]
12. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 activation as target to implement therapeutic treatments.
Bocci V; Valacchi G
Front Chem; 2015; 3():4. PubMed ID: 25699252
[TBL] [Abstract][Full Text] [Related]
14. miR340 suppresses the stem-like cell function of glioma-initiating cells by targeting tissue plasminogen activator.
Yamashita D; Kondo T; Ohue S; Takahashi H; Ishikawa M; Matoba R; Suehiro S; Kohno S; Harada H; Tanaka J; Ohnishi T
Cancer Res; 2015 Mar; 75(6):1123-33. PubMed ID: 25627976
[TBL] [Abstract][Full Text] [Related]
15. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
16. Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment.
Moon EJ; Giaccia A
Free Radic Biol Med; 2015 Feb; 79():292-9. PubMed ID: 25458917
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle.
Wurdinger T; Deumelandt K; van der Vliet HJ; Wesseling P; de Gruijl TD
Biochim Biophys Acta; 2014 Dec; 1846(2):560-75. PubMed ID: 25453365
[TBL] [Abstract][Full Text] [Related]
18. Stem cell niche irradiation in glioblastoma: providing a ray of hope?
Gupta T; Nair V; Jalali R
CNS Oncol; 2014; 3(5):367-76. PubMed ID: 25363009
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic KRAS confers chemoresistance by upregulating NRF2.
Tao S; Wang S; Moghaddam SJ; Ooi A; Chapman E; Wong PK; Zhang DD
Cancer Res; 2014 Dec; 74(24):7430-41. PubMed ID: 25339352
[TBL] [Abstract][Full Text] [Related]
20. Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas.
Coppola D; Balducci L; Chen DT; Loboda A; Nebozhyn M; Staller A; Fulp WJ; Dalton W; Yeatman T; Brem S
J Geriatr Oncol; 2014 Oct; 5(4):389-99. PubMed ID: 25220188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
